A jury has found that a vitamin C manufacturer based in China, as well as its affiliate company, are guilty of price-fixing in the US and have been ordered to pay $162 million. The $54.1 million in damages to the victims of the class action suit were trebled for Hebei Welcome Pharmaceutical Co Ltc, the vitamin C manufacturer. Sources say that the two defendants who were previously part of the case settled out of court for a reported $22.5 million. As CPI previously reported, the defendants had used a rare defense claiming that their company forced them to fix prices abroad, a defense known as the foreign sovereign compulsion doctrine.
Full Content: Thomson Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Japan’s Prime Minister Criticizes US Block on Nippon Steel-US Steel Deal
Feb 17, 2025 by
CPI
UAE Cabinet Announces New Merger Control Filing Thresholds Effective March 2025
Feb 17, 2025 by
CPI
UK Regulator Warns Topps Tiles Acquisition Could Hurt Competition
Feb 17, 2025 by
CPI
FTC Chair Andrew Ferguson Backs Trump’s Authority to Remove Commissioners
Feb 17, 2025 by
CPI
South Korea Suspends Downloads of Chinese AI App DeepSeek Over Data Privacy Concerns
Feb 17, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon